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Abstract
Background: The size and number of tumors are important prognostic indicators for hepatocellular carcinoma
(HCC). However, it is difficult to assess the prognosis for patients with a variable number and size of tumors. By
combining these two factors, we investigated the role and prognostic accuracy of total tumor volume (TTV) for
HCC.
Methods: A total of 786 patients undergoing locoregional therapy (transarterial chemoembolization, percutaneous
radiofrequency ablation and acetic acid or ethanol injection) for HCC were prospectively evaluated.
Results: The mean and median TTV was 177 cm
3 (range, 0.1-3,591 cm
3) and 21 cm
3, respectively. Of all, 38%, 29%,
15%, 7% and 11% of patients had TTV of <10 cm
3, 10-50 cm
3, 50-200 cm
3, 200-500 cm
3 and >500 cm
3,
respectively. TTV was significantly larger in patients with higher serum a-fetoprotein (AFP) levels or with vascular
invasion. The Child-Turcotte-Pugh score, performance status, vascular invasion, AFP level and TTV were significant
independent prognostic predictors in the Cox proportional hazards model. After adjustment, patients with TTV 50-
200 cm
3 (relative risk [RR]: 1.74, p = 0.009), 200-500 cm
3 (RR: 2.15, p = 0.006) and >500 cm
3 (RR: 3.92, p < 0.001)
had a significantly increased mortality risk in comparison to patients with TTV <10 cm
3.
Conclusions: TTV is a feasible prognostic predictor across a wide gradient and can be used to predict the
mortality risk of HCC. Selecting appropriate cutoffs of TTV may help refine the design of cancer staging system and
treatment planning. Future clinical trials of HCC may include this parameter for mortality risk stratification.
Background
Hepatocellular carcinoma (HCC) is one of the most
common malignant tumors in the world [1,2]. The prog-
nosis for patients with HCC is often very poor. Among
the reported prognostic predictors for HCC, the size
and number of tumor nodule, which represent tumor
burden, are frequently associated with the aggressiveness
of HCC and are of prime importance in determining the
clinical outcome of these patients [3-6]. The size and
number of tumor or the extent of tumor involvement
have also been included into the staging systems for
HCC [7]. In addition, the selection of treatment
modality for HCC is also highly dependent on the num-
ber and size of tumor nodule. For instance, the Milan
criteria are widely accepted standards for HCC patients
undergoing liver transplantation [8-10], whereas patients
undergoing partial hepatectomy usually have a maximal
tumor number of two or three. For patients undergoing
percutaneous ethanol or acetic acid injection or radio-
frequency ablation, the largest size of tumor is usually
set at 3 cm and the number of tumor nodule usually
does not exceed 3 [11,12]. However, for patients beyond
these criteria, the treatment selection may widely vary
and the prognostic prediction may become quite diffi-
cult. A major reason for this uncertainty and heteroge-
neity in cancer therapy is that a single determinant
representing tumor burden has not yet been specifically
defined. For example, the prognosis for a patient with a
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patient with 3 nodules with a tumor diameter of 4, 3
and 2 cm for each nodule. As such, it is difficult to
assess the prognosis for patients with a variable number
and size of tumor nodules, and this difficulty may make
the application of the currently used prognostic models
for HCC less practical and clinically feasible. The con-
cept of using total tumor volume (TTV) to represent
tumor burden has been proposed by independent study
groups [13,14]. By combining the factor of size and
number of tumor nodule, we aimed to define the tumor
burden by using TTV in assessing the long-term out-
come of patients with HCC. In this study, we have
investigated the feasibility of TTV, its association with
other clinical parameters and its predictive accuracy in
patients with HCC undergoing locoregional therapy.
Methods
Patients and diagnosis
Patients with newly diagnosed HCC in our hospital were
evaluated since April 2002. The clinical parameters in
these patients were prospectively assessed and recorded.
The diagnosis of HCC was histologically verified by nee-
dle biopsy, or based on the findings of typical radiologi-
cal features in at least two image examinations including
ultrasound, contrast-enhanced dynamic computed
tomography (CT), magnetic resonance imaging and
h e p a t i ca n g i o g r a p h y ,o rb yas i n g l ep o s i t i v ei m a g i n g
technique associated with serum a-fetoprotein (AFP)
level >400 ng/mL [15,16]. The underlying etiology of
liver disease was attributed to hepatitis B virus (HBV)
infection if patients were seropositive for hepatitis B sur-
face antigen (HBsAg, RIA kits, Abbott Laboratories,
North Chicago, IL, USA) and attributed to hepatitis C
virus (HCV) infection if patients were seropositive for
an antibody against HCV by a second-generation
enzyme immunoassay (Abbott Laboratories, IL). The
performance status was evaluated using the Eastern
Cooperative Oncology Group (ECOG) performance
scale: 0 (asymptomatic) to 4 (confined to bed). The
model for end-stage liver disease (MELD) score and
Child-Turcotte-Pugh (CTP) score were used to estimate
the severity of liver cirrhosis according to previous
reports [17-20]. The MELD score = 9.57 × loge (creati-
nine mg/dL) + 3.78 × loge (bilirubin mg/dL) + 11.2 ×
loge (international normalized ratio of prothrombin
time) + 6.43. Minimal values were set to 1.0 for calcula-
tion purposes. The maximal serum creatinine level con-
sidered within the MELD score equation was 4.0 mg/dL.
The CTP classification was based on serum levels of
albumin and bilirubin, prothrombin time prolongation,
and the severity of ascites and encephalopathy.
The Cancer of the Liver Italian Program (CLIP) was
used as the staging systems for HCC [7]. The presence
of ascites or vascular invasion by the tumors, and the
size and number of the each tumor nodule were deter-
mined and measured by the contrast-enhanced dynamic
CT scan. The volume of a tumor nodule was calculated
by using the following mathematical equation:
Tumor volume (cm ) 4/3 314
maximum radius of the tumor no
3 =× × .
d dule in cm
3 ()
TTV was the sum of the tumor volumes of every
nodule:
TTV (cm ) Tumor volume of 
tumor nodule 1 tumor nodule 2
3 =
++ … … + + () tumor nodule N
Treatment
All patients with a diagnosis of HCC and admitted to
our hospital would undergo initial evaluation for the
possibility of surgical resection. For patients with unre-
sectable lesions, curative or palliative locoregional ther-
apy including transarterial chemoembolization (TACE),
percutaneous acetic or ethanol acid injection (PAI, PEI),
or radiofrequency ablation (RFA) was performed
depending on the size and number of tumor nodules.
The selection of treatment modality and the details of
treatment procedure have been described in our pre-
vious studies [6,21-23]. Typically, percutaneous ablation
therapies were administered to patients with small
(<3 cm) tumor nodule and lesions no more than three.
TACE was indicated for patients with intermediate-sized
tumor or multi-nodular lesions. Malignant ascites, main
portal vein thrombosis by tumor invasion, or extrahepa-
tic tumoral spread indicated advanced cancer stage and
were contraindications for any forms of locoregional
therapy. Patients with clinical signs of viable or recur-
rent tumors after treatment were re-evaluated and re-
treated using the same or different treatment modality.
This study has been approved by the Institutional
Review Board of our hospital and complies with the
standards of Declaration of Helsinki and current ethical
guidelines.
Statistical analysis
The Chi-squared test or Fisher’s exact test was used for
categorical data, and the Mann-Whitney ranked sum
test was used for continuous data. The Kruskal-Wallis
test was used for the comparison across three or more
groups. Factors that may be associated with the survival
including age, gender, etiology of cirrhosis, CTP score,
MELD score, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), presence of ascites or vascular
invasion, serum AFP level, ECOG performance status
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Page 2 of 11and TTV, were included in the univariate survival
analysis. TTV was further categorized into five groups,
<10 cm
3, 10-50 cm
3, 50-200 cm
3, 200-500 cm
3 and
>500 cm
3, to determine its prognostic ability for outcome
prediction. Survival analysis between different groups of
patients was performed by using the Kaplan-Meir
method. The significance and relative risk (RR) of the
prognostic factors predictive of the survival in HCC
patients were determined and adjusted by using the mul-
tivariable Cox proportional hazards model. The adjusted
relative risks with 95% confidence intervals (CI) were
derived to assess the magnitude of the association
between various predictors and the risk or mortality. The
discriminatory ability of different staging system was
examined by using the Cox proportional hazards model,
and the consequences of the Cox model were expressed
with the Akaike information criterion (AIC), which
reveals how the staging systems affected the dependent
variable (patient survival) and represents an overall
assessment of a certain staging system [24,25]. The lower
the AIC, the more explanatory and informative the
model is [26]. Statistical significance levels were deter-
mined by 2-tailed tests. A p value < 0.05 was considered
statistically significant. All statistical analyses were con-
ducted using SPSS for Windows version 14 (SPSS Inc.,
Chicago, IL, USA) and MedCalc for Windows version 4.2
(MedCalc Software, Mariakerke, Belgium).
Results
Patient profiles
A total of 786 HCC patients who underwent locoregional
therapy during the period of April 2002 to June 2008
were enrolled and formed the basis of this study. The
baseline demographics of the study patients were shown
in Table 1. Patients were predominantly elderly (mean
age, 67 years) males (73%). Among them, 50% had evi-
dence of chronic HBV infection and 34% had evidence of
chronic HCV infection. The baseline MELD score was
9.3 ± 3.1, and 81% of the patients had a well-preserved
liver function (CTP class A). Five hundred (64%) patients
had a single tumor nodule, and 72% of patients had a
maximal tumor size of 5 cm or smaller. The mean and
median TTV was 177 cm
3 (range, 0.1-3,591 cm
3)a n d2 1
cm
3, respectively. Analysis of the distribution of TTV
showed that 38%, 29%, 15%, 7% and 11% of patients had
a TTV of <10 cm
3,1 0 - 5 0c m
3, 50-200 cm
3, 200-500 cm
3
and >500 cm
3, respectively. Of all patients, 60% had
undergone TACE, 28% had undergone RFA and 10% had
received PAI or PEI as the primary anti-cancer treatment.
Distribution and association of TTV and number and size
of tumor nodule
The size and number of tumor nodule in relation to
TTV were evaluated and shown in Table 2. For patients
Table 1 Baseline demographics
Number of patients 786
Age (mean ± SD years; range) 67 ± 12 (27-92)
Male/female (%) 73/27
Underlying liver disease (%)
HBsAg-positive 393 (50)
HBsAg-negative
Anti-HCV-positive 265 (34)
Anti-HCV-negative 128 (16)
Tumoral characteristics (%)
Single lesion 500 (64)
Multi-nodular lesions 286 (36)
Maximal tumor diameter
≤ 5 cm 566 (72)
>5 cm 220 (28)
Ascites (%)
Yes 101 (13)
No 685 (87)
Serum AFP level (ng/mL) (%)
Median (range) 29 (2-10,032,600)
<20 344 (44)
20 - 400 288 (37)
>400 154 (19)
Performance status (%)
ECOG scale 0 590 (75)
ECOG scale 1-3 196 (25)
Serum biochemistries (mean ± SD)
Albumin (g/dL) 3.7 ± 0.6
Bilirubin (mg/dL) 1.1 ± 1.0
Creatinine (mg/dL) 1.3 ± 3.2
Prothrombin time INR 1.1 ± 0.3
ALT (IU/L) 69 ± 68
AST (IU/L) 52 ± 44
Child-Pugh-Turcotte class (%)
A 639 (81)
B 147 (19)
MELD score (mean ± SD; range) (%) 9.3 ± 3.1 (6.4-23.9)
<8 336 (43)
8-11 215 (27)
>11 235 (30)
Vascular invasion (%)
No 699 (9)
Yes 87 (91)
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Page 3 of 11with uni-nodular or multi-nodular lesions, the TTV
significantly increased with increasing maximal tumor
diameter in the categories of <3 cm, 3-6 cm and >6 cm
(p < 0.0001). For the category of patients with maximal
tumor diameter <3 cm, the TTV tended to significantly
increase with the number of tumor nodules (p <
0.0001). However, there were no significant differences
of the TTV among the four groups (one, two, three and
four or more nodules) of patients with maximal dia-
meter of 3-6 cm (p = 0.054) and 6 cm (p = 0.177).
Association of TTV and tumoral and cirrhosis parameters
To determine the association between TTV and other
important prognostic indicators of HCC, the relationship
of TTV and serum AFP level, vascular invasion, CTP and
MELD score was investigated (Figure 1). TTV signifi-
cantly increased with increasing serum AFP levels (p <
0.0001). TTV was also significantly higher in patients
with vascular invasion (624 ± 774 cm
3)t h a np a t i e n t s
without vascular invasion (122 ± 334 cm
3; p < 0.0001).
However, there was no significant association between
TTV and the MELD (p = 0.21) or CTP (p = 0.412) score.
A total of 122 patients had a biopsy to evaluate tumor
histology: 39, 69 and 14 patients had well-, moderate-
and poorly-differentiated HCC respectively; there was no
significant difference among the grade of cell differentia-
tion and TTV (mean values: 89 ± 288, 94 ± 235 and 166
± 403 cm
3 respectively, p = 0.184).
Survival analysis
Up until July 2008, 216 (27%) patients died during a
mean follow-up period of 18 ± 14 months (range, 1-66
months). In the univariate survival analysis, ascites (p <
0.001), ECOG performance status (p < 0.001), vascular
invasion (p < 0.001), AFP level (p < 0.001), MELD score
(p = 0.04), CTP score (p < 0.001), AST level (p = 0.001)
and TTV (p < 0.001) were significant prognostic predic-
tors (Table 3). In the Cox proportional hazards model,
CTP score of 6 or higher (RR: 1.67, p < 0.001), ECOG
status 1 or higher (RR: 2.20, p < 0.001), vascular inva-
sion (RR: 2.14, p < 0.001), AFP level >100 ng/mL (RR:
1.50, p = 0.006) were significant independent prognostic
factors predicting a poor survival (Table 4). In addition,
there was an increasing trend of mortality risk across a
gradient of TTV in the Cox model. Compared with
patients with TTV <10 cm
3, the adjusted relative risk
for mortality was 1.13 (95% CI: 0.78-1.65, p = 0.514) for
patients with TTV 10-50 cm
3; 1.74 (95% CI: 1.15-2.64,
p = 0.009) for patients with TTV 50-200 cm
3; 2.15 (95%
CI: 1.24-3.72, p = 0.006) for patients with 200-500 cm
3;
3.92 (95% CI: 2.55-6.03, p < 0.001) for patients with
TTV >500 cm
3. The comparison of the survival rates
among the five categories of TTV was shown in Figure 2.
Table 2 Distribution of the number and size of tumor
and total tumor volume
No. of tumors and
patients, and total
tumor volume (cm
3)
Maximal tumor diameter (cm) p
<3 3-6 >6
One nodule
No. of patients 238 148 114
Total tumor volume 5 ± 4 44 ± 29 730 ± 692 <0.001
a
(median) (4) (34) (524)
Two nodules
No. of patients 73 45 32
Total tumor volume 7 ± 5
d 53 ± 29 720 ± 746 <0.001
b
(median) (6) (51) (372)
Three nodules
No. of patients 34 22 10
Total tumor volume 7 ± 5
e 45 ± 29 472 ± 429 <0.001
c
(median) (6) (33) (278)
Four or more nodules
No. of patients 34 21 15
Total tumor volume 10 ± 6
f 59 ± 41 937 ± 719
(median) (11) (66) (703)
p <0.001 0.054 0.177
Kruskal-Wallis test with post-test: a, b and c: p values all <0.05 for pairwise
comparison between the 3 groups; d vs e, d vs f and e vs f: p values all >0.05.
Table 1 Baseline demographics (Continued)
CLIP staging (%)
Score 0 266 (34)
Score 1 276 (35)
Score 2 141 (18)
Score 3 66 (8)
Score 4 or 5 37 (5)
Total tumor volume (cm
3) (%)
Mean ± SD (range) 177 ± 436 (0.1-3,591)
Median 21
<10 297 (38)
10-50 226 (29)
50-200 121 (15)
200-500 57 (7)
>500 85 (11)
Treatment (%)
PAI or PEI 79 (10)
RFA 221 (28)
TACE 471 (60)
More than one methods 15 (2)
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Page 4 of 11Figure 1 Association of the total tumor volume (TTV) with serum AFP level (panel A), vascular invasion (panel B), MELD (panel C) and
Child score (panel D). AFP level and vascular invasion, but not MELD and Child score, were significantly associated with TTV. Data were
expressed as median (horizontal bars) and 25% to 75% percentile of the distribution (lower and upper margin of the square); the upper and
lower vertical bars indicate 90% and 10% percentile of the distribution, respectively.
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Page 5 of 11Patients with the largest TTV had the highest cumulative
mortality rate, whereas patients with the smallest TTV
tended to have a better survival rate (p < 0.001).
Application of TTV in the staging system
To further investigate the feasibility of TTV in the can-
cer staging system, we have replaced the factor of tumor
character in the CLIP scoring system with TTV (<50
cm
3, 50-200 cm
3, 200-500 cm
3 and >500 cm
3; Table 5).
The modified CLIP system used a TTV-based scoring
method to re-stage all study patients. The mean scores
in the original and modified CLIP system were 1.2 ± 1.2
(range, 0-5) and 1.2 ± 1.5 (range, 0-7), respectively. In
the survival analysis, there was a significant difference in
the survival distribution across different score groups in
the original (p < 0.001; Figure 3A) and TTV-based (p <
0.001; Figure 3B) CLIP scoring system. The survival sig-
nificantly tended to be worse with increasing scores in
both models. The modified CLIP system had a lower
AIC value (3875.7) in comparison with the original
CLIP model (3969.6), suggesting a better predictive
accuracy for the TTV-based model.
Discussion
In this study, we have proposed a new prognostic predic-
tor, the TTV, for HCC, and have evaluated its feasibility
for outcome prediction. In most published literatures, the
traditional way to report the tumor burden of HCC is to
describe the size and number of tumor nodule simulta-
neously. However, it could be quite difficult or even con-
fusing to assess the prognosis of patients with a wide
range of number and size of tumor nodules. To solve this
problem, the factors of number and size of tumor nodule
are transformed into one single parameter in this study.
There are several clear advantages of this strategy. Firstly,
the TTV represents true tumor burden and can simplify
the way to describe the extent of tumor involvement in
liver. Secondly, TTV is a continuous variable that can be
easily calculated and used to predict the survival more
specifically. Alternatively, it can also be categorized into
different risk groups in terms of outcome prediction.
Thirdly, TTV can be incorporated into the staging system
for HCC because there was a significant dose-response
relationship between the TTV and long-term mortality
risk in our study. Notably, patients with TTV 50-200
cm
3, 200-500 cm
3 and >500 cm
3 had a significantly
increased mortality risk of 74%, 115% and 292%, respec-
tively, in comparison to patients with TTV <10 cm
3 after
adjusting for other significant prognostic variables in the
Cox analysis. These results indicate that TTV can serve
as an independent prognostic predictor for HCC.
In the five risk-stratified TTV groups, we found that
patients with TTV <50 cm
3 had a lower mortality risk
and patients with TTV >200 cm
3 had an increased
Table 3 Significance of the prognostic predictors in the
univariate survival analysis
Parameters No. of patients Survival rate (%) p
2-yr 4-yr
Age (years) 0.795
>60 554 68 39
≤ 60 232 70 37
Gender 0.713
Male 576 69 42
Female 210 71 29
HBsAg 0.589
Positive 393 68 42
Negative 393 70 34
Ascites <0.001
Yes 101 50 11
No 685 72 42
Performance status <0.001
ECOG 0 590 75 45
ECOG 1 or higher 196 51 10
Vascular invasion <0.001
Yes 87 35 22
No 699 72 41
AFP (ng/mL) <0.001
>100 253 58 33
<100 533 74 42
MELD score 0.04
>10 234 62 36
<10 552 72 40
CTP score <0.001
5 451 75 50
6 or higher 335 60 25
ALT (IU/L) 0.934
>40 499 70 38
≤ 40 287 67 40
AST (IU/L) 0.001
>40 551 65 31
≤ 40 235 77 52
Total tumor volume (cm
3) <0.001
<10 297 80 48
10-50 226 74 47
50-200 121 56 25
200-500 57 54 -
>500 85 34 10
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Page 6 of 11Figure 2 Comparison of the survival rates between five groups of patients with different total tumor volumes.
Table 4 Adjusted relative risks of the prognostic predictors in the Cox proportional hazards model
Predictors Regression coefficient Standard error Relative risk 95% CI p
Child score ≥ 6 0.51 0.15 1.67 1.25-2.23 <0.001
ECOG scale ≥ 1 0.79 0.15 2.20 1.63-2.97 <0.001
Vascular invasion 0.76 0.20 2.14 1.44-3.19 <0.001
AFP > 100 ng/mL 0.40 0.15 1.50 1.13-1.99 0.006
Total tumor volume
<10 cm
3 -- 1 - -
10-50 cm
3 0.13 0.19 1.13 0.78-1.65 0.514
50-200 cm
3 0.55 0.21 1.74 1.15-2.64 0.009
200-500 cm
3 0.77 0.28 2.15 1.24-3.72 0.006
>500 cm
3 1.37 0.22 3.92 2.55-6.03 <0.001
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Page 7 of 11mortality risk; the risk for patients with TTV between
50 to 200 cm
3 was considered intermediate. A TTV of
50 cm
3 is equivalent to a single tumor nodule with a
diameter of 4.6 cm. This cutoff is considered appropri-
ate for clinical application because TTV <50 cm
3 is
within the Milan criteria, suggesting the risk of tumor
recurrence is very low after liver transplantation or par-
tial hepatectomy [9,27]. On the other hand, a TTV of
200 cm
3 is equivalent to a single tumor nodule with a
diameter of 7.3 cm or three nodules the diameter in
each of which being 5 cm. Patients with TTV more
than 200 cm
3 belong to a relatively advanced cancer
stage that is beyond the University of California at San
Francisco criteria for liver transplantation [28,29].
Although selecting a cutoff to define the mortality risk
may be arbitrary in patients undergoing different thera-
peutic strategies, these two cutoffs of TTV may be used
for future reference in prognostic prediction.
T h er o l ea n dc l i n i c a ls i g n ificance of using TTV as a
prognostic predictor were validated in the staging system
for HCC. The CLIP scoring system is a widely used model
for prognostic stratification [8,30]. We found that using
TTV in the CLIP system could accurately predict the
outcome of patients in different score groups (Figure 3).
This result suggests that TTV is a feasible alternative indi-
cator of tumor burden for cancer staging.
An important implication of this study is that patients
with multi-nodular lesions may not necessarily have a
larger TTV (Table 2). This is because many patients had
a main tumor and several satellite lesions which could
be quite small. As a result, the calculated TTV in
patients with more tumor nodules was not necessarily
larger than that of patients with fewer number of tumor
nodules. This finding implicates that by reporting the
size and number of tumor nodule in HCC patients may
not be sufficient and sometimes could be misleading if
the actual tumor size for individual tumor nodule is not
mentioned. In this regard, reporting the value of TTV
i n s t e a do ft h es i z ea n dn u m b e ro ft u m o rn o d u l em a y
more accurately indicate the extent of tumor involve-
ment in liver.
TTV was also closely linked with serum AFP level and
the presence of vascular invasion. Both of these two fac-
tors are important tumor-associated parameters and
were also independent prognostic predictors in our ana-
lysis. Abundant studies consistently showed that these
two predictors may predict the survival of HCC patients
undergoing either surgical or non-surgical therapy
[31-39]. Since TTV can be used to reflect the status of
tumor burden, it is not surprising that a larger TTV is
expected to be more often associated with a higher AFP
level and vascular invasion. By contrast, it is anticipated
that TTV is not related to the severity of liver cirrhosis,
as indicated by the MELD and CTP score, in this study.
These findings suggest that TTV is an authentic tumoral
factor independent of the severity of liver cirrhosis.
In addition to serum AFP level, vascular invasion and
TTV, a higher CTP score and performance status were
also identified as independent prognostic predictors in
this study. A higher CTP score is known to correlate
with the severity of liver cirrhosis and could indepen-
dently predict the mortality risk. Performance status
represents the overall physical reserve in a given patient.
This parameter has been exclusively included in the
BCLC system which was suggested as the primary sta-
ging system for HCC [40], and our findings further con-
firm its role for prognostic prediction.
There are nevertheless a few potential limitations of
this study. Firstly, a shortcoming of using TTV is that
the estimation of tumor volume is based on the assump-
tion that all tumors are spherical. This estimate might
be erroneous if the tumor is irregular shaped. Secondly,
our results were derived from patients undergoing
locoregional therapy, therefore the strategy for selecting
appropriate cutoffs of TTV for patients receiving other
treatment modalities may not be the same. Thirdly, the
treatments used in individual patient were heteroge-
neous depending on the status of tumor spread and
Table 5 Risk score assessment according to the original
and total tumor volume (TTV)-based CLIP scoring system
Parameters Original CLIP TTV-based CLIP
Tumor morphology
Single and <50% liver span 0 -
Multiple and <50% liver span 1 -
≥ 50% liver span 2 -
Total tumor volume
<50 cm
3 -0
50-200 cm
3 -1
200-500 cm
3 -2
>500 cm
3 -3
Serum AFP level (ng/mL)
<400 0 0
≥ 400 1 1
Macroscopic vascular invasion
No 0 0
Yes 1 1
CTP class
A0 0
B1 1
C2 2
The score range is 0-6 for the original CLIP and 0-7 for TTV-based CLIP scoring
system.
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Page 8 of 11severity of cirrhosis. This may interfere with the assess-
ment of the impact of TTV on survival. Lastly, the TTV
in HCC patients with extrahepatic metastasis was not
considered in this study. The role of TTV as a prognos-
tic predictor in these far-advanced cancer stage patients
needs further studies to clarify.
Conclusions
Our results indicate that TTV is a feasible prognostic
predictor across a wide range of gradient and can be
used to predict the mortality risk in HCC patients
undergoing locoregional therapy. TTV can be easily and
readily obtained, and future clinical trials of HCC may
Figure 3 Comparison of the survival distributions between different score groups in the original and modified CLIP systems. There was
a significant difference in the survival distribution across all score groups in the original (p < 0.001; panel A) and TTV-based (p < 0.001; panel B)
CLIP scoring system. The survival significantly tended to be worse with increasing scores in both models.
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Page 9 of 11include this parameter for mortality risk stratification.
Selecting appropriate cutoffs of TTV may help refine
the design of cancer staging system and fine-tuning of
treatment planning.
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